TY  - JOUR
TI  - Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
AB  - Background/aim:  During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. Materials and methods:  This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients’ database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch. Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group. Conclusion:   The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.
AU  - nefati, Kiylioglu
AU  - Koseoglu, Mesrure
AU  - Gozubatik-Celik, Rabia Gokcen
AU  - DEMIRKIRAN, DURUHAN MELTEM
AU  - Demir, Caner Feyzi
AU  - BALGETİR, FERHAT
AU  - Altunrende, Burcu
AU  - Kamisli, Ozden
AU  - Tuncer, aslı
AU  - Sariahmetoglu, Hande
AU  - Uygunoglu, Ugur
AU  - Kürtüncü, Murat
AU  - Efendi, Hüsnü
AU  - Sevim, Serhan
AU  - ekmekci, ozgul
AU  - Akman-Demir, Gulsen
AU  - shugaiv, erkingül
AU  - olmez, cagcan
AU  - Kilinc Toprak, Munire
AU  - TERZI, HACI MURAT
AU  - özcan, abdulcemal
AU  - Baran Gazaloglu, Gulcan
AU  - Egilmez Sarıkaya, Cansu
AU  - YUCEYAR, NUR
AU  - Acar Ozen, Nazire Pinar
AU  - Beckmann, Yesim
AU  - Turkoglu, Recai
AU  - Göncüoğlu, Cansu
AU  - Soysal, Aysun
AU  - Boz, Cavit
AU  - turan, ömer faruk
AU  - Petek Balcı, Belgin
AU  - Aydin Canturk, Ilknur
AU  - Akcali, Aylin
AU  - canbaz kabay, sibel
AU  - KIZILAY, Ferah
AU  - Mavi, Kamil
AU  - YÜKSEL, SÜHA
AU  - ışık, nihal
AU  - Saip, Sabahattin
AU  - Karabudak, Rana
AU  - Siva, Aksel
AU  - ERAKSOY, MEFKURE
DO  - 10.55730/1300-0144.5588
PY  - 2023
JO  - Turkish Journal of Medical Sciences
VL  - 53
IS  - 1
SN  - 1300-0144
SP  - 323
EP  - 332
DB  - TRDizin
UR  - http://search/yayin/detay/1160999
ER  -